UNSPSC 51292918: Desipramine trifluoroacetate

This classification denotes a tricyclic antidepressant with the molecular formula C18H22N2.C2HF3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T6XJJ77M3, chemically known as acetic acid, trifluoro-, compd. with 10,11-dihydro-n-methyl-5h-dibenz(b,f)azepine-5-propanamine (1:1), but more generally known as desipramine trifluoroacetate, which bears US NIH Compound Identifier 151119.

European Medicines Agency schedules desipramine trifluoroacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06995MIG. Most nations, for tariff purposes, schedule desipramine trifluoroacetate under HS 29339990. SMILES: CNCCCN1C2CCCCC2CCC3C1CCCC3.C(=O)(C(F)(F)F)O.

UNSPSC 51292918 Desipramine trifluoroacetate is a Commodity code representing a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little direct relevance to desipramine itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical and pharmaceutical-adjacent procurement by state health agencies, counties, and cooperative purchasing alliances — including naloxone distribution, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products. State and local buyers under this code family include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating state and local government facilities across multiple states including Oregon and Minnesota).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a direct-to-manufacturer prescriptions program; and MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), effective July 1, 2026. The mismatch between the code's nominal chemical substance and the actual procurement activity suggests that state and local procurement offices may be using this code as a generic pharmaceutical identifier rather than a precise chemical match, making the code a broad signal for state and local pharmaceutical procurement rather than a precise targeting mechanism.